TNFRSF9 and chronic myelogenous leukemia, BCR-ABL1 positive: We found increased expression of TIM-3 (Percentage: 4.3 ± 2.7 vs. 7.7 ± 4.2; p = 0.0169), LAG-3 (Percentage: 0.3 ± 0.3 vs. 1.4 ± 1.5; p = 0.0013), and CD137 (Percentage: 0.6 ± 0.6 vs. 1.2 ± 0.9; p = 0.0326) in the NKT-like population from treated CML patients, when compared to HD group (Figure 6C).